Medicxi’s $10 Million Series B Investment Into Janpix


Goodwin Procter LLP advised Medicxi on the deal.

Medicxi announced its $10 million Series B investment into Janpix.

Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Janpix was launched in 2017 following seed financing by Medicxi. The Company’s aim is to advance the discovery and clinical development of selective STAT monovalent degraders based on new structural insights and chemistry developed by Prof Patrick Gunning, a Canada Research Chair in Medicinal Chemistry and co-founder. Janpix has identified small molecule degraders of STAT3 and STAT5 that show therapeutic potential in a number of hematological and solid tumors. Janpix is focused on advancing pre-clinical programs into the clinic for these difficult to treat and refractory indications.

The Goodwin team was led by Adrian Rainey (Picture) and Adam Thatcher.

Involved fees earner: Adrian Rainey – Goodwin Procter; Adam Thatcher – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Medicxi Ventures;